Unknown

Dataset Information

0

Carboplatin plus paclitaxel in combination with bevacizumab for the treatment of adenocarcinoma with interstitial lung diseases.


ABSTRACT: Interstitial lung diseases (ILDs) are frequently associated with lung cancer. The safety of carboplatin plus paclitaxel in combination with bevacizumab (CP-B) in patients with ILD and lung cancer (ILD-LC) remains to be clarified. In the present study, the safety and efficacy of CP-B treatment in ILD-LC patients were retrospectively investigated. Four patients, who completed CP-B therapy, were included in this study. The dose of carboplatin was the area under the curve 5, paclitaxel was 200 mg/m2 and bevacizumab was 15 mg/kg at treatment initiation. The patients were males, had histologically confirmed adenocarcinoma, were smokers and demonstrated non-usual interstitial pneumonia (non-UIP) patterns on computed tomography (CT). Patients received 1-6 cycles of CP-B therapy. Three of the four patients received maintenance bevacizumab therapy for 3-10 cycles. Only one patient demonstrated a partial response. Neutropenia was the most frequent adverse event. One patient experienced gut perforation during the first course of CP-B. No pulmonary toxicity was observed. Thus, treatment of ILD-LC patients with CP-B was not associated with pulmonary toxicity, however, this study population appeared to be at a low risk.

SUBMITTER: Suzuki H 

PROVIDER: S-EPMC3915637 | biostudies-other | 2013 May

REPOSITORIES: biostudies-other

altmetric image

Publications

Carboplatin plus paclitaxel in combination with bevacizumab for the treatment of adenocarcinoma with interstitial lung diseases.

Suzuki Hidekazu H   Hirashima Tomonori T   Kobayashi Masashi M   Okamoto Norio N   Matsuura Yuka Y   Tamiya Motohiro M   Morishita Naoko N   Okafuji Kohei K   Shiroyama Takayuki T   Morimura Osamu O   Morita Satomu S   Kawase Ichiro I  

Molecular and clinical oncology 20130301 3


Interstitial lung diseases (ILDs) are frequently associated with lung cancer. The safety of carboplatin plus paclitaxel in combination with bevacizumab (CP-B) in patients with ILD and lung cancer (ILD-LC) remains to be clarified. In the present study, the safety and efficacy of CP-B treatment in ILD-LC patients were retrospectively investigated. Four patients, who completed CP-B therapy, were included in this study. The dose of carboplatin was the area under the curve 5, paclitaxel was 200 mg/m<  ...[more]

Similar Datasets

| S-EPMC4881367 | biostudies-literature
| S-EPMC6179372 | biostudies-literature
| S-EPMC2834434 | biostudies-literature
| S-EPMC5925955 | biostudies-literature
| S-EPMC6976344 | biostudies-literature
| S-EPMC4669379 | biostudies-literature
| S-EPMC6790355 | biostudies-literature
| S-EPMC8551843 | biostudies-literature
| S-EPMC7811213 | biostudies-literature
| S-EPMC5830087 | biostudies-literature